acetate into metabolites. Taken together, these data show that acetate metabolism is not directly nor exclusively related to astrocytic metabolic activity, that use of acetate is related to enzyme acetylation and that acetate is directly metabolized to a significant degree in GABAergic neurons. Changes in acetate metabolism should be interpreted as modulation of metabolism through changes in cellular energetic status via altered enzyme acetylation levels rather than simply as an adjustment of glial-neuronal metabolic activity.
The brain, while preferentially metabolizing glucose, may also use other substrates to supply its energy needs, including monocarboxylates such as pyruvate, lactate, b-hydroxybutyrate and acetate. Brain metabolism of acetate, in particular, is known to be compartmentalized, with acetate believed to be metabolized largely in an astrocytic compartment (Van den Berg et al. 1966; Minchin and Beart 1975) . The evidence for this is based on the fact that the fractional enrichment of glutamine synthesized from labelled acetate is larger than the fractional enrichment of its glutamate precursor, indicating that the majority of acetate is metabolized in the same compartment as that which expresses glutamine synthetase, i.e. the astrocytic compartment. This observation led to the use of acetate as a marker for astrocyte metabolism (Sonnewald et al. 1993; Chapa et al. 1999) , with the caveat that this assumption was applicable for only a short period of time, and under specific circumstances (Badar-Goffer et al. 1990; Clarke 1999) .
The acetate/astrocyte compartmentation hypothesis was given a further boost by the claim that the reason acetate was preferentially metabolized in astrocytes was because of failure by neurons to take up acetate in any meaningful quantities (Waniewski and Martin 1998) . However, the recent determination of the affinity of the neuronal monocarboxylate transporter (MCT) 2 for acetate revealed that MCT2 has an affinity for acetate similar to that of other monocarboxylates and was therefore capable of facilitating acetate uptake into neurons and in fact did so (Rae et al. 2012) .
Instead of transport being the limiting factor for metabolism of acetate, the roadblock may lie in control of the metabolizing enzyme, acetyl-CoA synthetase (AceCS), which is subject to acetylation (Hallows et al. 2006) . Acetylation, or attachment of an acetyl group to lysine, is the second most common post-translational modification of proteins after phosphorylation (Minguez et al. 2012 ). In the case of AceCS, acetylation almost completely switches the enzyme off, providing a convenient route via which the enzyme can be controlled (Hallows et al. 2006 ). Whether or not this is the case in the brain remains unknown, although it is likely and would help explain the discrepancy between the data and the existing dogma.
There are two AceCS isoforms. AceCS1 shows a predominantly nuclear with weaker cytoplasmic expression (Ariyannur et al. 2010) . AceCS2 is a mitochondrial matrix enzyme and is likely the isoform most involved in oxidizing acetate (Fujino et al. 2001) . These enzymes are deacetylated and therefore activated by silent information regulators (SIRTs) 1 and 3 respectively. SIRTs are NAD + requiring enzymes which can link deacetylation activity to cell energy levels via NAD + availability (Fig. 1) . Although there are several candidate lysine acetyltransferases in the brain (KATs), the enzyme(s) responsible for the acetylation of AceCS isoforms has not yet been identified. This may not necessarily be an argument against the occurrence of acetylation of AceCS, as there are indications that acetylation occurs spontaneously and readily, including outside the favourable alkaline environment of the mitochondrion (Olia et al. 2015; Simic et al. 2015) .
The acetate/glucose experiment, whereby labelled acetate ([1,2-13 C]acetate) and labelled glucose ([1-13 C]glucose) are injected and metabolized, has traditionally been used to dissect metabolism that takes place in glia (mostly acetate) from glucose (all cell types) (Hassel et al. 1995; Nilsson et al. 2013) . It is not clear, however, under which conditions acetate metabolism can be increased, to what degree acetate is metabolized in other compartments in the brain or whether acetate metabolism can be increased by activating the AceCS1 deacetylating enzyme SIRT1 (Fig. 1) . Here, we studied metabolism of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate and [1- the Guinea pig cortical tissue slice, which allows manipulations of the environment which are not ethical or possible in vivo. First, we studied the effect on metabolism of a range of acetate concentrations to determine the optimal acetate concentration and to determine what effects acetate concentration may have on the metabolism of glucose. Then, we inhibited flux of 13 C into glutamine by inhibition of glutamine synthetase and also blocked uptake of glutamine into the neuronal compartment via System A to determine the contribution of glutamine labelled by [1,2-13C] acetate to the synthesis of GABA in neurons. We then activated astrocytic metabolism using potassium depolarization to see whether metabolism of acetate was increased under these circumstances and therefore was truly a reflection of astrocytic activity. Finally, we activated SIRT1 using the activator SRT1720 to see whether deacetylation of metabolic enzymes, including AceCS1, would have an effect on acetate metabolism.
Materials and methods
All experiments were conducted in accordance with the guidelines of the National Health and Medical Research Council of Australia and were approved by the institutional (UNSW) Animal Care Ethics Committee. Guinea pigs (female, Dunkin-Hartley, 400-800 g, obtained from South Australia Health and Medical Research Institute) were fed ad libitum on standard Guinea pig/rabbit pellets, with fresh carrots and hay roughage, and were maintained on a 12 h light/dark cycle.
Sodium [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate and [1-
13
C]D-glucose, and sodium [ 13 C]formate were purchased from Cambridge Isotope Laboratories Inc (Andover, MA, USA). SRT1720 (N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide hydrochloride) was purchased from AdooQ Bioscience (Irvine, CA, USA). L-Methionine sulfoximine (MSO; L-S-(3-amino-3-carboxypropyl)-S-methylsulfoximine) was purchased from Sigma-Aldrich (St Louis, MO, USA). All other reagents were of Analytical Reagent grade.
Brain cortical tissue slices were prepared as described previously (Br€ oer et al. 2007; Nasrallah et al. 2010; Rae et al. 2014) . Briefly, Guinea pigs were killed by cervical dislocation. The cortex was rapidly dissected from the brain and each cortex half dissected rostrocaudally and chopped using a McIlwain Tissue chopper (The Mickle Co., Surrey, United Kingdom). The resulting slices were immediately washed three times in a modified Krebs-Henseleit buffer (K-H Buffer; 124 mmol/L NaCl, 5 mmol/L KCl, 1.2 mmol/L KH 2 PO 4 , 1.2 mmol/L CaCl 2 , 1.2 mmol/L MgSO 4 and 26 mmol/L NaHCO 3 ) with continuous gassing with carbogen gas (95% O 2 /5% CO 2 ) containing 10 mmol/L D-glucose and resuspended in fresh buffer for a minimum of 40 min to allow metabolic recovery (Badar-Goffer et al. 1990 ). Prior to commencing each experiment, the slices from all Guinea pigs were pooled once more, washed three times in glucose free K-H buffer and divided into fresh flasks containing glucose free K-H buffer and the substrate(s) of choice.
The following experiments were performed: (Lundquist 1962) . Concentrations as high as 5 mM have been used in slice experiments previously (Badar-Goffer et al. 1990 ). The pH was adjusted to control pH levels in all cases where required. This experiment used the chopped cortices from eight Guinea pigs.
A further experiment was conducted under similar conditions with 5.0 mmol/L glucose and no acetate (control) or 2.0 or 5.0 mmol/L unlabeled acetate and incubated for 90 min to check for production of pyrophosphate under these conditions (Veech et al. 1986 ). This experiment used the chopped, combined cortices from six Guinea pigs. Slices were extracted by a single extraction chloroform/methanol technique. The aqueous phase was lyophilized and resuspended in D 2 O containing 2 mmol/L [ 13 C]formate, 2 mmol/L phenylphosphonate (a 31 P intensity and chemical shift marker (Clarke et al. 1994) ) and 4 mmol/L EDTA.
Effect of inhibiting glutamine synthetase activity with methionine sulfoximine Cortical tissue slices were incubated with 10 mmol/L D-glucose (control) and 1 mmol/L MSO for 30 min to allow for irreversible inhibition of glutamine synthetase (Ronzio et al. 1969; Jeitner and Cooper 2014) . Slices were then washed three times in glucose-free buffer and resuspended in fresh buffer (modified K-H buffer as described above) containing 0.4 mmol/L [1,2- A further experiment to test the effects of deprivation of glutamine from the neuronal compartment only was conducted. Cortical tissue slices were incubated with 10 mmol/L D-glucose and 1 mmol/L MSO for 30 min as described above. They were then washed three times in glucose-free buffer and resuspended in modified K-H buffer containing 0.4 mmol/L [1,2- (Br€ oer and Brookes 2001) . This transporter has been shown to be localized in the brain to glutamatergic and GABAergic neurons, with low level expression in ependymal cells and none in glial cells (Mackenzie et al. 2003) . This experiment used the chopped combined cortices of five Guinea pigs. After 90 min incubation, the experiment was stopped as described below.
Effect of potassium depolarization on acetate/glucose metabolism Potassium (40 mmol/L K + ) depolarization poses a high workload for brain tissue, particularly for astrocytes (Peng et al. 1994; Walz 2000) . Effect of activation of SIRT1 on acetate metabolism SRT1720 is an allosteric activator of SIRT1 (Hubbard et al. 2013) with 50% increase in activity (EC 1.5 ) at 0.16 lmol/L for SIRT1 and EC 1.5 of 37 lmol/L for SIRT2 (Milne et al. 2007; Pacholec et al. 2010) while it acts as an inhibitor at SIRT3 (IC 50 = 11 lmol/L) (Nguyen et al. 2013 (Nasrallah et al. 2008) . This experiment was part of a larger experiment investigating the effects of two concentrations of resveratrol and a higher concentration (16 lmol/L) of SRT1720. Resveratrol, while reported to be a SIRT1 activator has significant other metabolic effects, including interacting with mitochondrial respiration, while at higher concentrations, SRT1720 is an inhibitor of SIRT3 activity and has other effects (Milne et al. 2007 ). The resveratrol data have been published elsewhere (Rowlands et al. 2015) . This experiment used the combined chopped cortices of 10 Guinea pigs.
Following the end of each experimental period, slices were removed from the buffer by vacuum filtration and frozen in liquid nitrogen. Pulverized slices were then solvent extracted (Le Belle et al. 2002) and the aqueous phase lyophilized. The pellet was retained for protein estimation (Lowry et al. 1951) . The lyophilized extract was stored at À20°C until required for NMR analysis.
NMR
The lyophilized extracts were reconstituted in 0.5 mL 2 H 2 O containing 2 mmol/L [ 13 C]formate as an internal intensity reference, and 4 mmol/ L EDTA to chelate paramagnetic ions and remove localized field inhomogeneity, particularly for the citrate resonance. All spectra were acquired on a Bruker AVANCE III HD 600 spectrometer (Bruker, Billerica, MA, USA) fitted with a cryoprobe (TCI) and refrigerated sample changer. 1 H spectra were acquired, both with and without decoupling 13 C using bilev composite pulse decoupling, across an effective bandwidth of 48 000 Hz during the acquisition time, on a 30 s duty cycle, while 13 C{ 1 H-decoupled} spectra were acquired on a 4 s duty cycle using continuous WALTZ-65 decoupling. Total metabolite pool sizes were determined using TOPSPIN (v3.1) (Bruker, Billerica, MA, USA) from the 1 H{ 13 C-decoupled} spectra and the concentration of 13 C-labelled compounds from 13 C{ 1 H-decoupled} spectra, following appropriate adjustment for relaxation and nuclear Overhauser effect made according to previously acquired fully relaxed 13 C spectra as previously described (Rae et al. 2000) . All 31 P NMR spectra were acquired on a Bruker Avance III HD 600 spectrometer using a 5 mm TCI probe. Spectra were acquired across 32k data points (effective bandwidth 15 kHz) using an inverse-gated decoupling sequence on a 22 s duty cycle.
NMR data are presented in the following fashion: Total metabolite pools: Total pool size of metabolites were determined from the { 13 C}-decoupled 1 H NMR spectra and represents the total amount of any given metabolite found in the tissue extract.
Total label incorporation: This is determined from the { 1 H}-decoupled 13 C NMR spectrum and representing the total 13 C incorporated into any given carbon position. For example, for glutamate C4, this would include singly labelled Glu C4, plus Glu C4,3 and Glu C4,5.
We also detail label incorporated into specific isotopomers. In the case of glutamate C4, for example, this would include glutamate labelled solely at Glu C4, which is synthesized from [1-13 C]glucose (Fig. 2) , and Glu C4,5, which is synthesized from [1,2-13 C]acetate (Fig. 2) .
Statistical analyses
Data were compared using SPSS (IBM SPSS Statistics for Windows, version 22.0. IBM Corp, Armonk, NY, USA). Where more than two experimental conditions were compared, data was subjected to repeated measures ANOVA, with a statistical significance calculated by a post hoc Scheff e test, a = 0.05. If only two conditions were being compared, data was subjected to repeated measures ANOVA, followed by testing with MannWhitney U test to determine a p value, but only when the F-statistic indicated statistical difference. Only data that passed both those conditions were considered to be statistically significant. In the case of the MSO experiment, the control experiment (N = 4) was compared to the combined data from both MSO experiments for samples pre-incubated with 1 mmol/L MSO (N = 8) in order to determine the effects of MSO pre-incubation on metabolic activity. This was done using ANOVA followed by Mann-Whitney U test as described above for comparison of two groups. A further comparison was then conducted to compare the three remaining conditions: pre-incubation with 1 mmol/L MSO, pre-incubation with MSO with reintroduction of 0.4 mmol/L glutamine during the incubation period and pre-incubation with MSO with reintroduction of 0.4 mmol/L glutamine during the incubation period along with inhibition of System A using MeAIB. This was done using repeated measures ANOVA in SPSS followed by post hoc Scheff e test. Correlation between related isotopomers in the acetate concentration experiment was tested using linear regression in Graphpad Prism 6 (GraphPad Software, La Jolla, California, USA). The sample size for these experiments was based on historical data. Fig. 3 . Acetate had no significant effect on total metabolite pool sizes (data not shown) with no significant changes in total levels of lactate, glutamate, GABA, glutamine, aspartate, alanine, succinate or fumarate. Total labelling (i.e. label incorporated from either glucose or acetate substrates) of citrate was decreased with higher concentrations of acetate, while total labelling of Glu C4 was lower in the presence of 5.0 mmol/L acetate (1.83 AE 0.13 lmol/100 mg protein/90 min) than with 2.0 (2.27 AE 0.11 lmol/100 mg protein/90 min; p = 0.001) or 0.4 mmol/L acetate (2.22 AE 0.12 11 lmol/100 mg protein/ 90 min, p = 0.006; Fig. 3a) .
Results
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[1,2- C]D-glucose into citrate C2/4 (p = 0.001) with no significant change in label incorporation into Glu C4, GABA C2, Gln C4 and Asp C3 (Fig. 3b) .
Incorporation of label from [1,2-13 C]acetate ( Fig. 3c ) was highest in the 2 mmol/L acetate concentration experiment apart from label incorporation into Gln C4,5 which increased with increasing concentrations of acetate. The incorporation was not linear with a fivefold increase in acetate concentration (from 0.4 to 2.0 mmol/L) resulting in only a 20% increase in label incorporation. In the case of glutamate (p = 0.000), GABA (p = 0.021) and citrate (p = 0.036), label incorporation decreased significantly (compared to the 2 mmol/L samples, by 23%, 25% and 28%, respectively) with the higher (5.0 mmol/L) concentration of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C] acetate.
Taken together, these results suggest that the higher (5.0 mmol/L) concentration of acetate resulted in a decreased incorporation of label from all sources. Although the maximum incorporation of label from acetate was obtained with 2 mmol/L [1,2-13 C]acetate, the amount of increase compared to 0.4 mmol/L acetate was not proportional (i.e. not five times higher but only~20% higher), suggesting a decreased cost-benefit outcome. We therefore chose to use 0.4 mmol/L [1,2-13 C]acetate as the concentration of acetate in subsequent experiments, particular in the light of the suggestion that acetate is a low energy substrate that may trigger mitochondrial permeability transition pore (Veech et al. 1986) .
The 31 P NMR spectra of extracts from the experiment conducted with 5 mmol/L unlabeled glucose (control) with 2.0 or 5.0 mmol/L unlabeled acetate showed resonances from inorganic phosphate, ATP, phosphocreatine and various phosphomono-and diesters. The reaction catalysed by AceCS converts ATP to AMP and PPi (pyrophosphate), which may have a deleterious effect on several metabolic activities (Veech et al. 1986) . No resonance from PPi was detected in any sample (data not shown).
In this experiment, we also tested the correlation between GABA synthesized from [1,2-13 C]acetate, which is labelled at GABA C1,2, and both glutamine synthesized from [1,2- (Fig. 4) there should be a very strong correlation between Gln C4,5 and GABA C1,2 as label will need to pass from Glu C4,5 to Gln C4,5, be exported and taken up by GABAergic neurons before being converted to GABA (Tapia and Gonz alez 1978; Rae et al. 2003) . On the other hand, if glutamate is also synthesized in neurons from [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate, making Glu C4,5 and then converted directly to GABA C1,2, the correlation between Glu C4,5 and GABA C1,2 will be stronger than the correlation between Gln C4,5 and GABA C1,2 (Fig. 4) .
There was a strong correlation between Glu C4,5 and GABA C1,2 (r 2 = 0.81, p < 0.0001) and a weak correlation between Glu C4,5 and Gln C4,5 (r 2 = 0.36, p = 0.03) but no significant relationship between Gln C 4,5 and GABA C1,2 (r 2 = 0.25) (Fig. 4) . Similarly, GABA synthesized from [1- the Krebs cycle. The amount of Glu C4 correlated with GABA C2 very strongly (r 2 = 0.91, p < 0.0001) and moderately with Gln C4 (r 2 = 0.52, p < 0.007) while Gln C4 correlated less strongly with GABA C2 (r 2 = 0.43, p < 0.019) (Fig. 4) . To test whether blocking synthesis of glutamine in astrocytes had an effect on the incorporation of acetate into GABA, glutamine synthetase activity was blocked irreversibly by pre-incubation of slices with 1 mmol/L MSO. Integration of the cCH 2 resonance of glutamate in the proton spectrum was not possible because of significant overlap with resonances from MSO, but inspection of the { 13 -C}-decoupled 1 H spectrum showed significantly decreased amounts of glutamine (control 1.25 AE 0.12 vs. MSO 0.94 AE 0.12 lmol/ 100 mg protein; p = 0.008) and increased levels of aspartate (control 2.17 AE 0.21 vs. MSO 2.81 AE 0.24 lmol/100 mg protein (p = 0.008) and alanine control 1.10 AE 0.06 vs. MSO 2.13 AE 0.27 lmol/100 mg protein; p = 0.004), with no significant change in lactate (control 9.22 AE 0.60 vs. MSO 10.90 AE 1.6 lmol/100 mg protein) or GABA (control 3.69 AE 0.24 vs. MSO 3.69 AE 0.57 lmol/100 mg protein) levels. Total glutamine, although significantly reduced, was down to~75% of control levels, consistent with a large pool of metabolically inert glutamine as described previously (Rae et al. 2003) , although we note some difficulty in adequately resolving some of the glutamine multiplet from the large signal from MSO in the [ 13 C-decoupled} 1 H NMR spectrum.
After pre-incubation with MSO, there was no detectable labelling of any glutamine isotopomer compared to a value of 0.38 AE 0.02 lmol/100 mg protein/90 min for Gln C4 labelling under control conditions. Total net incorporation of label into Glu C2 (p = 0.028) and C4 (p = 0.004) was significantly increased by MSO treatment (Fig. 5) with the majority of this increase coming from increased net incorporation of [1,2- In summary, inhibition of glutamine synthetase significantly reduced incorporation of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate into GABA C1,2 while completely removing flux of label into Gln C4,5. C]acetate, along with the correlations between glutamine, glutamate and GABA species synthesized from these substrates. The strong correlation of GABA C1,2 with Glu C4,5 and the lack of a significant relationship between GABA C1,2 and Gln C4,5 suggests that the GABA C1,2 pool is more closely related to Glu C4,5 than to Gln C4,5 and, by inference, that GABA C1,2 is more likely to be synthesized from Glu C4,5 without first passing through a Gln C4,5 intermediate. added at the commencement of the 90 min incubation period. This was to create a condition where glutamine levels were restored but synthesis of glutamine from labelled compounds was not possible. C Same as B but with 10 mmol/L MeAIB added at the commencement of the 90 min incubation period. This was to prevent glutamine from entering the neuronal compartment by inhibition of System A glutamine uptake (Rae et al. 2003 ).
The addition of 0.4 mmol/L exogenous, unlabelled glutamine in the presence of 1.0 mmol/L MSO (condition B, above) restored total glutamine (MSO 0.94 AE 0.12 cf. 0.4 mmol/L Gln 2.52 AE 0.28 lmol/100 mg protein, p < 0.001) while blocking uptake of glutamine via System A with MeAIB in the presence of exogenous glutamine (condition C, above) had no further significant effect on total Gln compared to condition B (2.62 AE 0.14 lmol/100 mg protein; p = 0.77).
The net incorporation of 13 C into glutamate isotopomers Glu C4 and Glu C4,5 was significantly reduced in the presence of exogenous glutamine but was restored to levels seen in the presence of MSO alone by the inhibition of glutamine uptake by MeAIB (Fig. 5) . We interpret this as exogenous glutamine diluting the label in glutamate in condition B (above) but this was prevented when entry of exogenous glutamine was inhibited by MeAIB. From this, we conclude that the difference in label dilution between the added glutamine and the MeAIB conditions (conditions B and C, respectively) represents the fraction of glutamate being synthesized directly in the neuronal compartment where uptake of glutamine is inhibited by MeAIB. In the case of Glu C4,5, which is synthesized from [1,2-13 C]acetate this is around 20%. Net incorporation of label into GABA isotopomers, GABA C2 and GABA C1,2, was reduced by MSO and further reduced by addition of exogenous glutamine (Fig. 5) because of dilution of label. Competitive inhibition of System A uptake with MeAIB resulted in restoration of label incorporation to levels higher than in the presence of MSO but not to control levels suggesting that a significant proportion of the GABA could be supplied from local synthesis. Label supplied from [1-13 C]glucose (GABA C2) was restored nearly to control levels in the presence of MSO, exogenous glutamine and MeAIB (condition C) suggesting that GABA can be synthesized from glucose adequately under these circumstances without the supply of exogenous glutamine. By contrast, label supplied from [1,2-13 C]acetate was capable of supplying some, but not all of the synthesized GABA C1,2 (around 30%) when uptake of Gln C4,5 was inhibited with MeAIB ( Fig. 5) .
In the case of citrate, supply of exogenous glutamine reduced the accumulation of Cit C1,2 that occurred following inhibition of glutamine synthetase with MSO, while blockage of System A with MeAIB increased it once more, although it was not restored to the levels seen with MSO alone (p = 0.036; Fig. 5 ). This suggests that a significant proportion of the citrate synthesized from [1,2-13 C]acetate is synthesized in a compartment accessible to glutamine via System A.
Potassium depolarization
High potassium resulted in significant changes in incorporation of 13 C into metabolites as well as changes in metabolite pools. Potassium depolarization resulted in a significant increase in incorporation of 13 C into all measured metabolites ( Fig. 6a ) with more 13 C incorporated into slices under depolarizing conditions (sum of total 13 C incorporation = 8.72 AE 0.16 lmol/100 mg protein/40 min) than under control conditions (6.65 AE 0.13 lmol/100 mg protein/ 40 min, p = 0.029). Total lactate, alanine and glutamine were significantly (all p = 0.029) increased by depolarization while aspartate and GABA (p = 0.029) were decreased (Fig. 6c) . Slices subjected to depolarization had less residual glucose present in the slices after 40 min (p = 0.029), and incorporated more (Fig. 6b) , with label from [1-13 C]D-glucose increasing also (Cit C4; p = 0.029). There was also increased incorporation of label into both Glu C4 (labelled from glucose; p = 0.029) and Glu C4,5 (labelled from acetate; p = 0.029). This suggests acetate incorporation into the Krebs cycle was increased as far as 2-oxoglutarate with increased incorporation of both [1-
13
C]glucose and [1,2-13 C]acetate into glutamate isotopomers but that glutamine synthesis was increased from glucose at the expense of acetate.
Incorporation of acetate into GABA (GABA C1,2) was significantly decreased (reduced by 65%; p = 0.029) although incorporation of glucose into GABA was significantly greater (21%), suggesting that the glutamine being used to synthesize GABA under depolarizing conditions was derived from glucose rather than acetate.
SRT 1720
Incubation of brain cortical tissue slices with the SIRT1 allosteric activator SRT 1720 (0.16 lmol/L) significantly increased incorporation of 13 C into metabolites associated with the Krebs cycle, such as glutamate, aspartate and citrate, and also increased incorporation into GABA and glutamine (all p = 0.029) but reduced incorporation of 13 C into metabolites associated with glycolysis (lactate and alanine; Fig. 7a : p = 0.029).
Inspection of the contributions of each substrate to these changes showed that incorporation of label from [1,2-13 C] acetate was significantly increased in the presence of the SRT 1720 (0.16 lmol/L) with increased labelling of Glu C4,5, Gln C4,5 and Asp C3,4 (p = 0.029, Fig. 7b ), indicating that metabolism of acetate is increased when SIRT1 is more active. Metabolism of [1-
13 C]glucose is also increased, with increased incorporation of label into Glu C2 Glu C4, GABA C2, Gln C4, Asp C3, Citrate C2 (all p = 0.029) but decreased incorporation into Lac C3 and Ala C3 (all p = 0.029), indicating a higher relative pyruvate clearance rate. Incorporation of label into the Krebs cycle-related isotopomers derived from [1-13 C]glucose (Glu C4, Gln C4, GABA C2, Asp C3 and Cit C2/4) was increased by 25% while incorporation of label into the Krebs cycle-related isotopomers derived from [1,2-13 C]acetate increased by 43% suggesting that SIRT1 activation had a relatively larger effect on acetate metabolism than on that of glucose. SRT 1720 (0.16 lmol/L) increased the total metabolic pool of glutamine (1.63 AE 0.09 lmol/100 mg protein), control; 1.93 AE 0.16 lmol/100 mg protein, SRT 1720, p = 0.029) and decreased the pool of lactate (11.1 AE 0.49 lmol/100 mg protein, control; 9.66 AE 0.70 lmol/ 100 mg protein, SRT 1720: p = 0.029) with no significant effect on any of the other measured metabolite pools.
Discussion
Effect of increasing acetate concentration on acetate metabolism We found maximum incorporation of label from [1,2-13 C] acetate, in competition with 5 mmol/L [1-
13 C]glucose, to occur at an acetate concentration around 2 mmol/L (Fig. 3) .
Incorporation of label is already~80% of this maximum at a fivefold lower concentration of 0.4 mmol/L. The exception to this was incorporation of label into Gln C4,5 which was maximal at 5 mmol/L [1,2-13 C]acetate; the concentration previously reported as appropriate in cortical tissue slices based on glutamine fractional enrichment (Badar-Goffer et al. 1990) . This difference in incorporation into isotopomers depending on the starting concentration suggests that there may be several acetate metabolizing compartments in the brain including an astrocytic one which favours incorporation of acetate into glutamine and which is capable of metabolizing more acetate than other compartments.
Acetyl-CoA is a key metabolite in energy metabolism and the levels of it are very highly regulated (Shi and Tu 2015) . Acetate has only one entry point into metabolism, via AceCS, an ATP-dependent reaction which can be deactivated by lysine acetylation and reactivated by deacetylation (Hallows et al. 2006) . From a metabolic control point of view, it makes sense that this reaction is also highly regulated in order to maintain the levels of acetyl-CoA within tight bounds. Metabolism in the brain of alternative substrates, such as lactate, pyruvate and glucose follow hyperbolic kinetics, with increased concentrations resulting in increased metabolism up to an asymptote at which maximal respiration is reached (McIlwain and Bachelard 1985) ; this does not appear to be the case for acetate which fails to increase respiration (Bollard and McIlwain 1957) , suggesting that its metabolism is regulated via a different mechanism to that of glucose, lactate and pyruvate. This has been, historically, an accepted fact, although the dispute has been around the mechanism. In 1998, it was suggested that the reason acetate displayed only limited metabolism in neurons was as a result of failure by these cells to take up acetate in any significant amount (Waniewski and Martin 1998) . This failure, in the presence of data showing good expression of AceCS in neurons, was attributed to lack of affinity for acetate by the neuronal MCT2. However, subsequent measurement of the affinity of MCT2 for acetate showed that MCT2 is indeed capable of transporting acetate (Rae et al. 2012 ); in addition, there is also a sodium-dependent monocarboxylate transporter (SMCT1 or SLC5A8) found in neurons (Martin et al. 2006) which displays an even higher affinity for acetate than MCT2 (Babu et al. 2011) . Others have shown that the uptake of acetate into the brain is not the limiting factor for acetate metabolism (Deelchand et al. 2009b) , suggesting it is the metabolism itself (Patel et al. 2010) .
The results from the experiment in this work conducted using increasing concentrations of acetate suggest several things. Label incorporation from [1,2- labelled from a small glutamate pool (Berl and Frigyesi 1969) and another pool which labels a fraction of a larger pool of glutamate and GABA (Cerdan et al. 1990) .
Further, it is apparent that acetate at high (5.0 mmol/L) concentrations has a deleterious effect on overall metabolic rate, with decreased incorporation of label from any source into aspartate and citrate. [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]Acetate competed successfully with [1-13 C]glucose only for label incorporation into glutamine.
Incorporation of acetate into metabolism requires conversion of acetate to acetyl-CoA in the reaction catalysed by AceCS (E.C. 6.2.1.1); this reaction requires ATP and produces pyrophosphate, the accumulation of which has been shown to decrease the free [NAD + ]/[NADH] ratio and have deleterious effects on mitochondrial metabolism (Veech et al. 1986) . Pyrophosphate is also involved in the recycling of NAD + after its consumption by NAD-ases; it is a cofactor in the conversion of nicotinamide to nicotinamide-mononucleotide catalysed by nicotinamide phosphoribosyltransferase (Garten et al. 2009) and it is also an inhibitor of nicotinamide mononucleotide adenylyltransferase, being released in the conversion of nicotinamide-mononucleotide to NAD + (Schweiger et al. 2001) . Here, we report no significant level of pyrophosphate being detected in the brain following metabolism of acetate up to 5 mmol/L although it has previously been reported in liver extracts following incubation with ketone bodies (Veech et al. 1986 ). Pyrophosphate is not normally present in brain tissue extracts (Glonek et al. 1982) and the brain has an active pyrophosphatase (Gordon 1950) . Taken together, this indicates that build-up of pyrophosphate is unlikely to explain the deleterious effects of increased acetate concentration in this organ.
Metabolism of acetate in neurons
The question is whether the acetate used to label glutamate and GABA is supplied via glutamine sourced from astrocytes as suggested previously (Cerdan et al. 1990) , or whether it is synthesized directly in a neuronal compartment.
[1,2-13 C]Acetate is used to synthesize GABA (Fig. 2) , labelling GABA specifically at GABA C1,2. The high correlation between the concentration of Glu C4,5 and GABA C1,2, as opposed to the weaker relationship between Gln C 4,5 and GABA C 1,2, which parallel the correlations between Glu C4 and GABA C2 (synthesized from [1-13 C] glucose) and Gln C4 and GABA C2 (Fig. 4) suggested that a significant proportion of the Glu C4,5 is being converted directly to GABA C1,2, as is the Glu C4 to GABA C2 rather than being first converted to glutamine in the astrocyte and exported to GABAergic neurons to make GABA. While this observation is in agreement with those of Tapia and Gonzalez (Tapia and Gonz alez 1978) , that under resting conditions most GABA is synthesized from glutamate, it does indicate that significant amounts of glutamate may be being synthesized from acetate in neurons and that, subsequently, this glutamate is being used in GABAergic neurons to make GABA.
In order to investigate this further, we undertook some experiments with the glutamine synthetase inhibitor MSO. Incubation of slices with MSO significantly reduced the amount of GABA C1,2 in the slices while Gln C4,5, from which the GABA would be derived if it were made from acetate synthesized in neurons, was abolished. This suggested that around a third of the GABA labelled from acetate was derived directly in the neuron from [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate, with the remainder supplied via Gln C4,5. However, the metabolic profile in the presence of MSO suggested that slice metabolism might be altered in a deleterious fashion by the eradication of glutamine synthetase activity and the subsequent reduction in glutamine levels which might cause additional effects over and above simply removing glutamine labelling. Accordingly, we conducted a further series of experiments where we reintroduced glutamine exogenously, which restored metabolic pool sizes, and then blocked entry of glutamine into the neuronal compartment using an inhibitor of System A, which has been shown previously to supply glutamine for synthesis of GABA (Chaudhry et al. 2002; Mackenzie et al. 2003) .
Under these circumstances, when synthesis of glutamine was blocked with MSO and glutamine was prevented from entering the neuronal compartment, synthesis of Glu C4,5 and GABA C1,2 increased significantly over the experiment with exogenous glutamine alone (Fig. 5 ), indicating that [1,2-13 C]acetate was indeed being used to synthesize GABA, and also, likely, glutamate, in neurons.
Glutamine is lost to the external medium at an appreciable rate in slices. Our data (unpublished) shows a loss of glutamine to the buffer after 1 h of incubation in Guinea pig slices of around 36%, which is lower than the amount reported in slices of the rat or mouse brain. Guinea pig slices are larger and have a smaller surface to volume ratio. However, this loss of glutamine may dilute the amount of glutamine labelled at C4,5 that can contribute to the synthesis of GABA C1,2 when transferred to neurons. Allowing for this loss, we calculate that 28% of the GABA synthesized from acetate is synthesized directly in neurons. We also note that loss of glutamine occurs in vivo, with glutamine being lost to the cerebrospinal fluid.
In addition, a change in the flux of glucose via the pentose phosphate pathway could potentially lead to a differential loss of label. Pentose phosphate pathway dilution of glutamate C4 label has been estimated at 1% (Hyder et al. 1996) although Dienel points out that this could increase 2.3-fold in activated conditions (Dienel and Cruz 2009) . These are relatively minor effects and not likely to have a significant impact on acetate fluxes.
Finally, it must be considered that the situation in vivo may differ from that reported here. Slice metabolism is considerably slower than that in vivo and slices are generally considered to be more glycolytic, producing high amounts of lactate when stimulated, for example (Fig. 6c) .
Is acetate metabolism related to astrocytic metabolic activity, or not? As detailed in the introduction to this work, the metabolism of acetate in vivo has been used as a surrogate measure for astrocytic metabolic activity (e.g. (Boumezbeur et al. 2010; Hassel et al. 1995; Lebon et al. 2002; Lanz et al. 2014) ) based on the assumption that incorporation of acetate into glutamate and glutamine is representative of the astrocytic Krebs cycle. Here, we activated astrocytes using potassium depolarization which is reported particularly to activate astrocytes because of their role in maintaining potassium homeostasis (Hertz 1965; Walz 2000) .
While potassium depolarization resulted in significantly increased overall metabolism in slices, there was a significant difference in the substrates contributing to this depolarization (Fig. 6) . It is known that use of glucose by slices and by neuroglial cocultures increases under depolarizing conditions (Badar-Goffer et al. 1992; Takahashi et al. 1995) but the role played by acetate under these conditions is not clear (Badar-Goffer et al. 1992 ). An experiment conducted in the rat brain in vivo using topical application of potassium for depolarization showed increased uptake of [ 14 C]acetate under these conditions, and tentatively assigned this to increased astrocytic metabolism, but was not able to identify the fate of the accumulated acetate (Dienel et al. 2001) . In subsequent work, Dienel et al. (2007) showed increased acetate uptake under graded photic stimulation, but cautioned that it was not correlated with the cerebral metabolic rate of glucose use in active or resting structures (Dienel et al. 2007) . It also may be that the use of tracer amounts of acetate as in radiolabelling studies does not perturb metabolism in the same way as the introduction of higher amounts of 13 C. Here, we showed that acetate oxidation decreased under depolarizing conditions by~23% compared to an increase in use of glucose of~35%, calculated by summing the total isotopomer contributions from each substrate and comparing these to the control experiment.
Under depolarizing conditions, the alterations in acetate metabolism displayed an interesting pattern of changes. Acetate incorporation into citrate (C1,2) was hugely increased by depolarization, and incorporation into Glu C4,5 (Fig. 6b) was also increased. By contrast, the amount of 13 C from acetate incorporated into Gln C4,5 was decreased by~45% and into GABA C1,2 by~65% (Fig. 6b) .
Citrate synthesis from glucose was also increased. The fate of the citrate synthesized from acetate was unclear; no citrate was found in 1 H or 13 C spectra of the buffer solution from either depolarizing or control conditions, indicating that it was not exported from the slices in significant quantities, but was retained intracellularly.
Taken together, these results show that acetate metabolism is significantly decreased when astrocytes are activated by potassium depolarization. Further, the pattern of incorporation of [1,2 13 C]acetate into the Krebs cycle-related metabolites is altered, with increased incorporation into citrate, modest increases in incorporation into glutamate and decreased incorporation into glutamine, GABA and aspartate. This contrasts steeply with the metabolism of glucose, which is uniformly increased (Fig. 6b) . This experiment, at least, shows direct violation of the assumptions about acetate metabolism representing astrocytic activity underlying the classical application of glucose/acetate labelling experiments (Deelchand et al. 2009a) .
Acetate metabolism in the presence of SIRT1 activating compound SRT 1720 SIRT1 is a lysine deacetylase with deacetylation activity reported at enzymes such as AceCS1 (Hallows et al. 2006) , phosphoglycerate mutase 1 (Hallows et al. 2012) glyceraldehyde-phosphate dehydrogenase (Joo et al. 2012 ) and pyruvate dehydrogenase (Jian et al. 2014) . In the brain, AceCS1 has strong nuclear expression as well as light to moderate cytoplasmic expression in neurons, axons, astrocytes and oligodendrocytes (Ariyannur et al. 2010) . Based on the current literature, it is suggested that in the brain, SIRT1 expression is predominantly in the nucleus of neurons with the ability to shuttle to the cytoplasm where it can interact with multiple proteins. SIRT1 has been identified to be highly expressed in neurons that are located in brain regions such as the cortex, hippocampus, cerebellum and hypothalamus and specific nuclei in brainstem (Ramadori et al. 2008; Zakhary et al. 2010) . Distribution patterns of SIRT1 have been further characterized by (Zakhary et al. 2010) , who provided evidence that SIRT1 expression is colocalized with GABA containing neuronal populations in the CA1 and Purkinje neurons. SIRT1 expression is predominantly in the nucleus of many cells but, depending on Chromosomal Maintenance 1 (CRM1)-mediated nuclear exportation signal it can be shuttled to the cytoplasm (Tanno et al. 2007; Hisahara et al. 2008) . Indeed, some subsets of neurons predominantly express SIRT1 in cytoplasm (Tanno et al. 2007) .
At the concentration used here (16 lmol/L), we would expect SRT-1720 to activate SIRT1 specifically and have negligible effects on SIRT2 and SIRT3 and also negligible other reported effects (Pacholec et al. 2010) . Stimulation of SIRT1 with SRT-1720 has previously been shown to increase oxygen consumption in a SIRT-1-dependent fashion (Feige et al. 2008 ) and also to increase incorporation of label from [3- suggesting that stimulation of acetate metabolism was not universal, in keeping with the compartmentalized location of SIRT1.
Conclusions
In summary, here we show that acetate metabolism is compartmentalized in the brain taking place in an astrocytic subcompartment which makes glutamine, but also, under circumstances, such as potassium depolarization, using the acetate to produce citrate. Acetate itself produces inhibitory effects on metabolism, with one compartment of acetate metabolism showing optimal incorporation of acetate around 2 mmol/L acetate, while incorporation into glutamine is further enhanced by increasing acetate concentrations to 5 mmol/L. Caution should be exercised in inferring that levels of acetate metabolism are related to astrocytic activity as depolarization with potassium leads to significantly decreased acetate use. Acetate is also metabolized in GABAergic neurons, with around 30% of the GABA synthesized from [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate directly in neurons and not from astrocyte-supplied Gln C4,5.
There is capacity to increase use of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate through stimulation of SIRT1 activity; stimulation of AceCS2 through activation of SIRT3 remains to be explored once a suitable SIRT3 activator becomes available.
Finally, the acetate/glucose experiment remains a powerful tool to explore metabolism. Our data suggest to interpret changes in acetate metabolism as modulation of metabolism through changes in cellular energetic status via altered enzyme acetylation levels rather than simply as a binary, two-compartment adjustment in metabolic activity.
